Harnessing the antibacterial and immunological properties of mucosal-associated invariant T cells in the development of novel oral vaccines against enteric infections

Abautret-Daly, Áine; Davitt, Christopher J. H.; Lavelle, Ed C.

doi:10.1016/j.bcp.2014.08.017

Cited by 8 publications

(5 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their localisation at mucosal sites, immune-modulating capacity and the availability of known ligands for both invariant natural killer (iNKT) cells and mucosal-associated invariant T (MAIT) cells has attracted interest in targeting these cells to potentiate immune responses to orally delivered antigens [135,136]. Another novel oral adjuvant strategy has been the administration of live bacterial adjuvants such as Bacillus Calmette-Guérin (BCG), Lactobacillus plantarum or L. rhamnosus together with inactivated simian immunodeficiency virus (SIV).…”

Section: Mucosal Adjuvantsmentioning

confidence: 99%

“…The relative abundance of cell populations such as iNKT and MAIT cells, activators of which may present novel adjuvant opportunities, also vary along the GIT but seem to be predominantly located in the jejunum [34,135]. Additionally specific DC subsets vary in abundance in different regions of the GIT, making the targeting of individual subsets reliant on the correct anatomical localisation of the delivery system [34].…”

Section: Targeted Delivery To Specific Tissues and Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Delivery strategies to enhance oral vaccination against enteric infections

Davitt

Lavelle

2015

Advanced Drug Delivery Reviews

Self Cite

132

108

View full text Add to dashboard Cite

Section: Mucosal Adjuvantsmentioning

confidence: 99%

Section: Targeted Delivery To Specific Tissues and Cellsmentioning

confidence: 99%

Delivery strategies to enhance oral vaccination against enteric infections

Davitt

Lavelle

2015

Advanced Drug Delivery Reviews

Self Cite

132

108

View full text Add to dashboard Cite

“…Unconventional T cells such as invariant natural killer T (iNKT) cells or mucosal-associated invariant T (MAIT) cells have been considered as potential adjuvant targets: Intestinal sites are enriched in these cells which are at the interface between innate and adaptive immunity and can modulate APCs [85]. Some iNKT cell agonists have been investigated as adjuvants to enhance immune responses in immunotherapy and vaccination strategies [86].…”

Section: Oral (Gastrointestinal) Vaccinesmentioning

confidence: 99%

Technological Approaches for Improving Vaccination Compliance and Coverage

et al. 2020

Self Cite

View full text Add to dashboard Cite

Vaccination has been well recognised as a critically important tool in preventing infectious disease, yet incomplete immunisation coverage remains a major obstacle to achieving disease control and eradication. As medical products for global access, vaccines need to be safe, effective and inexpensive. In line with these goals, continuous improvements of vaccine delivery strategies are necessary to achieve the full potential of immunisation. Novel technologies related to vaccine delivery and route of administration, use of advanced adjuvants and controlled antigen release (single-dose immunisation) approaches are expected to contribute to improved coverage and patient compliance. This review discusses the application of micro- and nano-technologies in the alternative routes of vaccine administration (mucosal and cutaneous vaccination), oral vaccine delivery as well as vaccine encapsulation with the aim of controlled antigen release for single-dose vaccination.

show abstract

“…MAIT cells have been proposed to be a potential target of mucosal vaccination [37], and further study on such interventions is needed.…”

Section: Mait Cellsmentioning

confidence: 99%

Innate-like lymphocytes in intestinal infections

Bennett

Round

Leung

2015

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Structured Abstract Purpose of review The mechanisms of immunity against intestinal pathogens are not well understood. Innate-like lymphocytes are a group of recently discovered cells that do not fit into either side of the historical innate-adaptive classification. They are enriched in the intestinal mucosa and participate in gut homeostasis and defense against infections. We will review recent developments in innate-like T lymphocytes and innate lymphoid cells (ILCs), specifically as they relate to responses to intestinal infections. Recent findings Recent studies have uncovered further details into antigen presentation to γδ T cells and mucosal-associated invariant T (MAIT) cells, the role of invariant natural killer T cells and MAIT cells in intestinal infections, and how ILCs maintain gut homeostasis and protection. Summary Innate-like lymphocytes play a major role in the critical early response to intestinal infections and maintaining gut homeostasis. Further studies of the roles these cells play in the human intestinal mucosa will aid in the development of therapeutics against intestinal infections.

show abstract

Harnessing the antibacterial and immunological properties of mucosal-associated invariant T cells in the development of novel oral vaccines against enteric infections

Cited by 8 publications

References 82 publications

Delivery strategies to enhance oral vaccination against enteric infections

Delivery strategies to enhance oral vaccination against enteric infections

Technological Approaches for Improving Vaccination Compliance and Coverage

Innate-like lymphocytes in intestinal infections

Contact Info

Product

Resources

About